PRESS INFORMATION
6 December 2002
ELEMENTIS plc ANNOUNCES COMPLETION OF CHROMIUM ACQUISITION
Elementis is pleased to announce that the acquisition of the chromium chemicals business of US based Occidental
Chemical Corporation, OxyChem completed today. As previously announced the acquisition was made for an initial cash
consideration of $40 million and up to $6 million in deferred consideration contingent on future performance.
The former OxyChem operation at Castle Hayne, North Carolina now becomes Elementis Chromium's primary US operation
producing dichromate and chromic acid to serve the North American market.
Work is now progressing on the smooth integration of operations with emphasis on high standards of customer service and
driving cost savings. Elementis believes that the acquisition and integration of OxyChem's chromium chemical business
will generate significant cost savings through optimising operations, reducing overhead and procurement costs and
obtaining supply chain benefits. As previously announced, annualised cost savings of at least £10 million will be
generated during the first two years. One-time cash costs of restructuring the combined business are estimated to be
£4 to £5 million in 2002.
- Ends -
Enquiries
Elementis 01784 224212
Brian Taylorson Finance Director
Anna Passey Head of Corporate Communications
Brunswick 020 7404 5959
Andrew Fenwick
Chi Lo
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.